(Q37795337)

23 August 2017

title

The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). (English)

1 reference

23 August 2017

1 reference

Olivier Cussenot

3

0 references

Morgan Rouprêt

series ordinal

4

object named as

Morgan Rouprêt

1 reference

23 August 2017

François Audenet

1

1 reference

23 August 2017

David R Yates

series ordinal

2

1 reference

23 August 2017

publication date

29 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

31

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

407-413

1 reference

Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The long-term outcome after laparoscopic nephroureterectomy: a comparison with open nephroureterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Chemotherapy of urothelial tract tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Behavior of Urothelial Carcinoma With Respect to Anatomical Location

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Microsatellite Instability in Urothelial Carcinoma of the Upper Urinary Tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

The role of chemotherapy in upper tract urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

Molecular and histological markers in urothelial carcinomas of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.016

10.1016/J.UROLONC.2010.07.016

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference